A Randomized, Double-blind, Placebocontrolled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)with Type 2 inflammation | AVESİS

Manisa Celal Bayar Üniversitesi Akademik Veri Yönetim Sistemi

A Randomized, Double-blind, Placebocontrolled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)with Type 2 inflammation

YORGANCIOĞLU A. A. (Yürütücü)

Diğer Uluslararası Fon Programları, 2019 - 2023

Proje Türü: Diğer Uluslararası Fon Programları
Başlama Tarihi: Mart 2019
Bitiş Tarihi: Eylül 2023